Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Neumora logo — Pioneering a new era of medicines for brain diseases

Neumora

Pioneering a new era of medicines for brain diseases

Founded 2020 United States Watertown, United States 111 employees Series B Total: $612.00M Biotechnology, Health Care

General Information

Company Name Neumora
Founded Year 2020
Location United States Watertown, United States
Founders / Decision Makers
Team member Team member
Employees 111
Industries Biotechnology, Health Care
Funding Stage Series B
Business Model B2B, D2C
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Neumora. To contact Neumora, visit neumoratx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Neumora compare?

A PDF of Neumora and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Neumora soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Neumora

Neumora, founded in 2020 in the United States, is a pioneering company in the Biotechnology and Health Care industries, with a mission to redefine treatment methodologies for brain diseases. Operating under the slogan, "Pioneering a new era of medicines for brain diseases," Neumora addresses a critical unmet medical need affecting over 1.5 billion global patients.

The company adopts a unique precision neuroscience approach to develop novel therapies focusing on both neuropsychiatric and neurodegenerative disorders. Their pipeline currently includes seven programs at various stages, targeting new mechanisms to substantially improve patient outcomes and quality of life.

Neumora's strategic roadmap recently received significant validation with a $112.00M Series B investment on 11 October 2022, backed by renowned investors such as Arch Venture Partners, F-Prime Capital, Polaris Partners, Invus, and others, underscoring investor confidence in its innovative approach and transformative potential.

Business keywords: brain diseases, neuroscience, neuropsychiatric disorders, neurodegenerative diseases, precision neuroscience, novel mechanisms of action, clinical-stage biotechnology, psychiatric treatments, neuroscience drug development, data science integration, novel therapies, pipeline development, therapeutic innovation, brain health, clinical programs

Services & Products

Development of precision medicines for brain diseases
Drug pipeline targeting novel mechanisms of action
Integration of translational, clinical, and computational tools

Target Customers

Patients with brain diseases Medical professionals in neurology and psychiatry Healthcare providers focused on CNS disorders

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $112.00M 10
Arch Venture Partners F-Prime Capital Polaris Partners
Arch Venture Partners, F-Prime Capital +8
11 Oct 2022
Series A $400.00M -
07 Oct 2021
Corporate Round $100.00M -
07 Oct 2021
Venture Round Undisclosed -
01 Oct 2018

Neumora Alternatives & Competitors

View All Alternatives
Neumora vs
Gate Neurosciences
Gate Neurosciences United States

Brain Health, Reimagined

Venture round
15 employees
Biotechnology, Health Care
Compare Neumora vs Gate Neurosciences
Neumora vs
ProJenX
ProJenX United States

ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhibitors for ALS & oth...

Series A
9 employees
Biopharma, Biotechnology
Compare Neumora vs ProJenX
Neumora vs
Psy Therapeutics
Psy Therapeutics United States

Creating new futures in central nervous system (CNS) treatment and care.

Seed
11 employees
Biotechnology, Health Care
Compare Neumora vs Psy Therapeutics
Also compare with: Neumora vs Rapport Therapeutics Rapport Therapeutics Neumora vs Vigil Neuroscience Vigil Neuroscience View all alternatives

FAQ About Neumora

Pioneering a new era of medicines for brain diseases
Neumora was founded in 2020.
Neumora is headquartered in Watertown, United States.
Neumora operates in Biotechnology and Health Care. Its work centres on brain diseases, neuroscience, neuropsychiatric disorders and neurodegenerative diseases. Its customers include Patients with brain diseases, Medical professionals in neurology and psychiatry and Healthcare providers focused on CNS disorders.
Neumora has a B2B and D2C business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Neumora has approximately 111 employees.
Neumora has completed 4 funding rounds, raising a total of $612.00M. The latest funding stage is Series B.
Neumora offers: Development of precision medicines for brain diseases, Drug pipeline targeting novel mechanisms of action, Integration of translational, clinical, and computational tools.
Top alternatives and competitors to Neumora include Gate Neurosciences, ProJenX, Psy Therapeutics, Rapport Therapeutics, Vigil Neuroscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neumora and Gate Neurosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Neumora, https://bouncewatch.com/company/neumora-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout